Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Novo Nordisk reportedly failed to pay its annual fees to maintain the patent rights in Canada, opening the door to cheaper ...

The 24-year study of more than 1.2 million children in Denmark found that aluminum exposure didn't raise the risk of autism, asthma, or other chronic diseases. Other science and research news is on ...

Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared ...

Ozempic Might Be a Dementia Buster, Too Research out today is the latest to suggest that semaglutide can significantly lower people's risk of dementia. By Ed Cara Published June 24, 2025 ...

A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could lower your risk of developing dementia.

Compared with other antidiabetic drugs, semaglutide is associated with a lower risk for Alzheimer disease-related dementia in patients with type 2 diabetes.

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Results from this study show that there is a direct correlation between the use of anti-obesity medications and testosterone levels,” the study author said.

Binge eating disorder is strongly associated with weight gain and obesity, though not all individuals with obesity have BED.

Three studies presented today at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether ...

Researchers found that the active ingredient in Ozempic may lower the risk of dementia in people with type 2 diabetes.